uniQure (NASDAQ:QURE) Sees Large Volume Increase – Here’s What Happened

uniQure (NASDAQ:QURE) saw unusually-strong trading volume on Wednesday . Approximately 681,525 shares changed hands during mid-day trading, a decline of 27% from the previous session’s volume of 930,653 shares.The stock last traded at $16.08 and had previously closed at $17.64.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on QURE shares. Cantor Fitzgerald upped their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Royal Bank of Canada upped their target price on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Mizuho upped their target price on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

The company has a market capitalization of $675.09 million, a price-to-earnings ratio of -2.79 and a beta of 0.41. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a 50 day simple moving average of $11.23 and a 200 day simple moving average of $7.96.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. As a group, research analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. abrdn plc lifted its holdings in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of uniQure in the 3rd quarter worth approximately $7,360,000. Point72 Asset Management L.P. boosted its position in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the period. FMR LLC boosted its position in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the period. Finally, Privium Fund Management B.V. boosted its position in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.